首頁 › 轉移性癌症 › 猶他州 › Salt Lake City
Salt Lake City, UT 的 轉移性癌症 臨床試驗
20 項針對 轉移性癌症 的研究正在 Salt Lake City（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
招募中1 期
- University of Utah - Huntsman Cancer Institute, Salt Lake City
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- Intermountain Health, Salt Lake City
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
招募中2/3 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
招募中1/2 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
招募中3 期
- Huntsman Cancer Institute, Salt Lake City
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
招募中3 期
- Utah Cancer Specialists, Salt Lake City
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
招募中1/2 期
- University of Utah - Huntsman Cancer Institute, Salt Lake City
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
招募中1 期
- University of Utah, Salt Lake City
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
招募中1 期
- Huntsman Cancer Institute/University of Utah, Salt Lake City
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
招募中1/2 期
- Crinetics Study Site, Salt Lake City
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
招募中1/2 期
- Utah Cancer Specialists, Salt Lake City
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
招募中1 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
招募中1 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
招募中1 期
- Huntsman Cancer Institute, Salt Lake City
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
招募中1/2 期
- Huntsman Cancer Institute, Salt Lake City
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
招募中1/2 期
- Huntsman Cancer Institute, Salt Lake City
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
招募中2 期
- Huntsman Cancer Institute at University of Utah, Salt Lake City
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
招募中1/2 期
- Utah Cancer Specialists (site 203), Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Salt Lake City
其他城市的 轉移性癌症 試驗
- Houston, TX104 項研究
- New York City, NY93 項研究
- Nashville, TN70 項研究
- Boston, MA63 項研究
- Los Angeles, CA57 項研究
- St. Louis, MO54 項研究
- Arlington, VA53 項研究
- Philadelphia, PA46 項研究
- Chicago, IL45 項研究
- San Antonio, TX44 項研究
- Washington, DC43 項研究
- Dallas, TX42 項研究
Salt Lake City 的其他研究
- 非小細胞肺癌31 項研究
- 癌症（所有類型）27 項研究
- 乳癌27 項研究
- 大腸直腸癌22 項研究
- 肺癌21 項研究
- 黑色素瘤21 項研究
- 多發性骨髓瘤21 項研究
- 卵巢癌19 項研究
- 肥胖症18 項研究
- 急性髓系白血病17 項研究
- 心臟衰竭17 項研究
- 前列腺癌15 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。